NEFL and Alzheimer disease: Future studies should include additional biomarkers, e.g., CSF biomarkers of neuroinflammation (YKL-40) and neurodegeneration (NfL) or blood-based AD biomarkers, which might show a stronger correlation between blood-based DNAm.